Inhalation Formulation Market is expected to reach US$ 60,157 2 Million, at a CAGR of 3 7% Through 2 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterAnnounced positive.
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023
Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial.
WALTHAM - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. , today announced that XACDURO is now available in the United States for patients 18 years of age and older for the.
Innoviva, Inc. , a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside.